Continuous low-dose cyclophosphamide and prednisone in the treatment of relapsed/refractory multiple myeloma with severe heart failure

References

• Vázquez FJ, Funtowicz G, Rivello HG, et al. Nodular hepatic lesions secondary to multiple myeloma. Medicina (B Aires) 2010; 70:311–315.
   PubMed Web of Science ®Google Scholar
• Trotti A, Byhardt R, Stetz J, et al. Common toxicity criteria: version 2.0. An improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:13–47.
   Google Scholar
• Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000;105:1045–1047.
   PubMed Web of Science ®Google Scholar
• Stempak D, Gammon J, Halton J, et al. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors. J Pediatr Hematol Oncol 2006;28:720–728.
   PubMed Web of Science ®Google Scholar
• Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423–436.
   PubMed Web of Science ®Google Scholar
• Coleman M, Martin P, Ruan J, et al. Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leuk Lymphoma 2008;49:447–450.
   PubMed Web of Science ®Google Scholar
• Kropff M, Bisping G, Schuck E, et al. Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007;138:330–337.
   PubMed Web of Science ®Google Scholar
• Herrlinger U, Rieger J, Steinbach JP, et al. UKT-04 trial of continuous metronomic low-dose chemotherapy with methotrexate and cyclophosphamide for recurrent glioblastoma. J Neurooncol 2005;71:295–299.
   PubMed Web of Science ®Google Scholar
• Browder T, Butterfield CE, Kräling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878–1886.
   PubMed Web of Science ®Google Scholar
• Garcia AA, Hirte H, Fleming G, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008; 26:76–82.
   PubMed Web of Science ®Google Scholar
• Wong NS, Buckman RA, Clemons M, et al. Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J Clin Oncol 2010;28:723–730.
   PubMed Web of Science ®Google Scholar
• Nicolas P, Antoine A, Guido B. Cyclophosphamide-based metronomic chemotherapy:After 10 years of experience, where do we stand and where are going? Crit Rev Oncol Hematol 2012;82:40–50.
   PubMed Web of Science ®Google Scholar
• Trieu Y, Trudel S, Pond GR, et al. Weekly cyclophosphamide and alternate-day prednisone:an effective, convenient, and well-tolerated oral treatment for relapsed multiple myeloma after autologous stem cell transplantation. Mayo Clin Proc 2005;80:1578–1582.
   PubMed Web of Science ®Google Scholar
• Suvannasankha A, Fausel C, Juliar BE, et al. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: a Hoosier Oncology Group Trial, HEM01-21. Oncologist 2007;12:99–106.
   PubMed Web of Science ®Google Scholar
• Zhou F, Guo LP, Shi HT, et al. Continuous administration of low-dose cyclophosphamide and prednisone as a salvage treatment for multiple myeloma. Clin Lymphoma Myeloma Leuk 2010;10: 51–55.
   PubMed Web of Science ®Google Scholar
• Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467–1473.
   PubMed Web of Science ®Google Scholar
• The Criteria Committee of the New York Heart Association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels. 9th ed. Boston, MA: Little, Brown & Co, 1994. pp 253–256.
   Google Scholar
• Stacey JW, Alan HB, Robert C, et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am Heart J 2002;144:834–839.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. Available from: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf
   Google Scholar
• Kumar SK, Lee JH, Lahuerta JJ, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012;26:149–157.
   PubMed Web of Science ®Google Scholar
• Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649–655.
   PubMed Web of Science ®Google Scholar
• Seino Y, Ogawa A, Yamashita T, et al. Application of NT-proBNP and BNP measurements in cardiac care: a more discerning marker for the detection and evaluation of heart failure. Eur J Heart Fail 2004;6:295–300.
   PubMed Web of Science ®Google Scholar
• Rickard J, Cheng A, Spragg D, et al. Durability of survival effect of cardiac resynchronization therapy by level of left ventricular functional improvement: fate of “non-responders”. Heart Rhythm 11/2013. DOI:10.1016/j.hrthm.2013.11.025. [Internet]
   Google Scholar
• Anderson KC, Alsina M, Bensinger W, et al. Multiple myeloma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 2007;5:118–147.
   PubMedGoogle Scholar
• Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3–9.
   PubMed Web of Science ®Google Scholar
• Goolsby MJ. National Kidney Foundation Guidelines for chronic kidney disease: evaluation, classification, and stratification. J Am Acad Nurse Pract 2002;14:238–242.
   PubMedGoogle Scholar
• Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423–436.
   PubMed Web of Science ®Google Scholar
• Robin J, Fintel B, Pikovskaya O, et al. Multiple myeloma presenting with high-output heart failure and improving with anti-angiogenesis therapy: two case reports and a review of the literature. J Med Case Rep 2008;2:229–234.
   Google Scholar